Connect Biopharma Holdings Limited Operating Expenses
Connect Biopharma Holdings Limited (CNTB) reported Operating Expenses of $20.37 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-12
- Connect Biopharma Holdings Limited operating expenses for the quarter ending 2026-06-30 was $20.37M, a 51.22% increase year-over-year.
- Connect Biopharma Holdings Limited operating expenses for the quarter ending 2026-03-31 was $19.78M, a 72.76% increase year-over-year.
- Connect Biopharma Holdings Limited operating expenses for the quarter ending 2025-12-31 was $15.53M, a 50.49% increase year-over-year.
- Connect Biopharma Holdings Limited operating expenses for the quarter ending 2025-09-30 was $17.69M, a 17.44% increase year-over-year.
- Connect Biopharma Holdings Limited operating expenses for fiscal 2025 was $58.14M, a 19.91% increase from fiscal 2024.
- Connect Biopharma Holdings Limited operating expenses for fiscal 2024 was $48.48M, a 29.79% decline from fiscal 2023.
- Connect Biopharma Holdings Limited operating expenses for fiscal 2023 was $69.06M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $20.37M 10-Q · filed 2026-08-12 | $40.15M 10-Q · filed 2026-08-12 | $55.67M derived: sum of 3 quarters · filed 2026-08-12 | $73.37M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $19.78M 10-Q · filed 2026-05-12 | $35.30M derived: sum of 2 quarters · filed 2026-05-12 | $52.99M derived: sum of 3 quarters · filed 2026-05-12 | $66.47M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $15.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $33.22M derived: sum of 2 quarters · filed 2026-03-31 | $46.69M derived: sum of 3 quarters · filed 2026-08-12 | $58.14M 10-K · filed 2026-03-31 |
| 2025-09-30 | $17.69M 10-Q · filed 2025-11-12 | $31.16M derived: sum of 2 quarters · filed 2026-08-12 | $42.61M 10-Q · filed 2025-11-12 | $52.93M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $13.47M 10-Q · filed 2026-08-12 | $24.92M 10-Q · filed 2026-08-12 | $35.24M derived: sum of 3 quarters · filed 2026-08-12 | $50.30M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $11.45M 10-Q · filed 2026-05-12 | $21.76M derived: sum of 2 quarters · filed 2026-05-12 | $36.83M derived: sum of 3 quarters · filed 2026-05-12 | $47.30M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $10.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $25.38M derived: sum of 2 quarters · filed 2026-03-31 | $35.85M derived: sum of 3 quarters · filed 2026-03-31 | $48.48M 10-K · filed 2026-03-31 |
| 2024-09-30 | $15.06M 10-Q · filed 2025-11-12 | $25.54M derived: sum of 2 quarters · filed 2025-11-12 | $38.17M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $10.47M 10-Q · filed 2025-08-13 | $23.10M 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $12.63M 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $69.06M 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |